Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Onkologie|September 22, 2011
Cancer patients and the Internet: a survey of the 'Quality of Life' Working Groups of the Arbeitsgemeinschaft für Internistische Onkologie and the Nord-Ostdeutsche Gesellschaft für Gynäkologische OnkologieDeniz Gencer, Felix Tauchert, Nina Keilhauer, et al.
Oncology Research and Treatment|September 17, 2024
Guidelines of Onkopedia: What Is New? Locally Advanced Rectal CancerRalf-Dieter Hofheinz, Dirk Arnold, Markus Borner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2011
Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinomaJ Randolph Hecht, Tanja Trarbach, John D Hainsworth, et al.
Oncotarget|May 17, 2017
Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapyStefan Kasper, Henning Reis, Sophie Ziegler, et al.
The Lancet. Oncology|September 13, 2015
Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trialSusanna Hegewisch-Becker, Ullrich Graeven, Christian A Lerchenmüller, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2023
Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trialsAlessandra Raimondi, Federico Nichetti, Arndt Stahler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 30, 2024
Negative Hyperselection of Resistance Mutations for Panitumumab Maintenance in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa Phase II Trial, AIO KRK 0212)Arndt Stahler, Andreas J Kind, Christine Sers, et al.
Clinical Colorectal Cancer|August 2, 2020
Biweekly Cetuximab Plus FOLFOX6 as First-Line Therapy in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The CEBIFOX TrialStefan Kasper, Johannes Meiler, Heike Knipp, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 30, 2025
Spatial tumor immune microenvironment as a prognostic and predictive biomarker in anti-EGFR-based maintenance for RAS wt metastatic CRC - the PanaMa (AIO KRK0212) trialAlexej Ballhausen, Susanna Swoboda, David Horst, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2021
Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212)Dominik Paul Modest, Meinolf Karthaus, Stefan Fruehauf, et al.
Pageof 5